Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma

Inclusion Criteria: * Age ≥18 years. * Has pancreatic ductal adenocarcinoma * Has resectable disease at the time of diagnosis * Has not received any systemic therapy for pancreatic ductal adenocarcinoma * Has stage ≤ IIb disease at time of diagnosis and enrollment * Elevated tumor marker, CA (carbohydrate antigen) 19-9 \>200 * ECOG performance status 0 or 1 * Patient must have adequate organ function defined by the study-specified laboratory tests. * Must use acceptable form of birth control while on study. * Ability to understand and willingness to sign a written informed consent document. Exclusion Criteria: Patients who have received any prior chemotherapy, radiotherapy or investigational agents for pancreatic cancer. * Patients who have received prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4, or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137). * Has received prior therapy with FAK inhibitor. * Woman who are pregnant or breastfeeding. * Have received a live vaccine or live-attenuated vaccine within 30 days prior to study drug. * Is currently or has participated in another investigational study within 4 weeks prior to receiving study drug. * History or current use of immunosuppressive medications within 7 days prior to study medications. * Has a known additional malignancy that is progressing or has required active treatment within the past 2 years or that is expected to require active treatment within two years. * Has active autoimmune disease that has required systemic treatment in the past 2 years. * Has a history of (non-infectious) pneumonitis/interstitial lung disease or current pneumonitis. * Has an active infection requiring systemic therapy. * Infection with HIV or hepatitis B or C. * Patient with uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * Known allergy or hypersensitivity to the study drugs. * Received any growth factors including, but not limited to, granulocyte-colony stimulating factor (G-CSF), GM-CSF, erythropoietin, within 14 days of study drug administration. * Has history of any organ transplant, including corneal transplants.